SCHEMBL30790744

SCHEMBL30790744

COc1cc(N2CCC(CO)CC2)ccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.45
SMARCA4 P51532 1/20 0.45
CHRM4 P08173 2/20 0.44
SUV39H2 Q9H5I1 2/20 0.43
CHRM1 P11229 1/20 0.43
CHRM2 P08172 1/20 0.43
PSEN1 P49768 7/20 0.43
PSEN2 P49810 7/20 0.43
APH1B Q8WW43 7/20 0.43
NCSTN Q92542 7/20 0.43
APH1A Q96BI3 7/20 0.43
PSENEN Q9NZ42 7/20 0.43
ITGB2 P05107 1/20 0.41
ICAM1 P05362 1/20 0.41
ITGAL P20701 1/20 0.41
CYP17A1 P05093 1/20 0.41
ACVR1 Q04771 1/20 0.41
HRH4 Q9H3N8 1/20 0.40
ACACB O00763 1/20 0.40
CDK1 P06493 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26156898 0.82 SMARCA2 (0.46) SMARCA2SMARCA4CHRM4CHRM1PSEN1
SCHEMBL16684915 0.81 SMARCA2 (0.47) SMARCA2SMARCA4SUV39H2PSEN1PSEN2
Hydrochloric Acid SCHEMBL2275791 0.80 SMARCA2 (0.46) SMARCA2SMARCA4SUV39H2PSEN1PSEN2
Hydrochloric Acid SCHEMBL16684752 0.80 SMARCA2 (0.46) SMARCA2SMARCA4SUV39H2PSEN1PSEN2
SCHEMBL4391755 0.80 CHRNB2 (0.58) CHRM4SUV39H2HRH4
SCHEMBL786061 0.79 HRH4 (0.55) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL30790732 0.79 SUV39H2 (0.40) SUV39H2PSEN1PSEN2APH1BNCSTN
SCHEMBL15114940 0.78 ADRB1 (0.56) SMARCA2SMARCA4HRH4
SCHEMBL14788209 0.78 MAPK8 (0.46) CHRM4PDE10A
SCHEMBL16691292 0.78 PSEN1 (0.50) SMARCA2SMARCA4CHRM4PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055108-A1 TRIAZINE COMPOUNDS AND USES THEREOF HUTCHMED LTD (CN) 2026-02-26 US disclosed
EP-4581032-A1 TRIAZINE COMPOUNDS AND USES THEREOF HUTCHMED Limited (CN) 2025-07-09 EP disclosed
WO-2024046457-A1 TRIAZINE COMPOUNDS AND USES THEREOF HUTCHMED LIMITED (CN) 2024-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260055108-A1 TRIAZINE COMPOUNDS AND USES THEREOF CBR1, CNR1, CBR3 SMARCA2 3011/4885SMARCA4 3070/4885CHRM4 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.